INIS
eyes
100%
newborns
80%
control
60%
comparative evaluations
60%
levels
40%
safety
40%
plasma
40%
diseases
20%
data
20%
surfactants
20%
risks
20%
morbidity
20%
administration
20%
interventions
20%
populations
20%
oxygen
20%
lasers
20%
Keyphrases
Retinopathy of Prematurity
100%
Microdroplet
100%
Propranolol
100%
Historical Controls
30%
Plasma Parameters
20%
Oral Propranolol
20%
Risk Ratio
10%
Randomized Placebo-controlled Trial
10%
Comorbidity
10%
Historical Data
10%
Incidence Rate
10%
Demographic Characteristics
10%
Biochemical Parameters
10%
No Adverse Effect
10%
Ophthalmic Examination
10%
Open-label Trial
10%
Photocoagulation Treatment
10%
Apgar Score
10%
Oxygen Exposure
10%
Surfactant Administration
10%
β-adrenoceptor
10%
Proliferative Phase
10%
Data Risk
10%
Perinatal Characteristics
10%
Laser Photocoagulation
10%
Medicine and Dentistry
Propranolol
100%
Retinopathy of Prematurity
100%
Neonatal Infant
36%
Disease
9%
Placebo
9%
Hemodynamic
9%
Adverse Event
9%
Beta Adrenergic Receptor
9%
Open-Label Trial
9%
Laser Coagulation
9%
Apgar Score
9%
Comorbidity
9%
Surfactant
9%
Pharmacology, Toxicology and Pharmaceutical Science
Propranolol
100%
Retrolental Fibroplasia
100%
Disease
9%
Placebo
9%
Adverse Event
9%
Surfactant
9%
Beta Adrenergic Receptor
9%
Open-Label Trial
9%
Comorbidity
9%